dc.contributor.author | Legrand, AJ | |
dc.contributor.author | Choul-Li, S | |
dc.contributor.author | Villeret, V | |
dc.contributor.author | Aumercier, M | |
dc.coverage.spatial | Switzerland | |
dc.date.accessioned | 2023-10-10T12:41:08Z | |
dc.date.available | 2023-10-10T12:41:08Z | |
dc.date.issued | 2023-08-30 | |
dc.identifier | ARTN 13454 | |
dc.identifier | ijms241713454 | |
dc.identifier.citation | International Journal of Molecular Sciences, 2023, 24 (17), pp. 13454 - | |
dc.identifier.issn | 1422-0067 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/6007 | |
dc.identifier.eissn | 1422-0067 | |
dc.identifier.doi | 10.3390/ijms241713454 | |
dc.description.abstract | ETS transcription factors are a highly conserved family of proteins involved in the progression of many cancers, such as breast and prostate carcinomas, Ewing's sarcoma, and leukaemias. This significant involvement can be explained by their roles at all stages of carcinogenesis progression. Generally, their expression in tumours is associated with a poor prognosis and an aggressive phenotype. Until now, no efficient therapeutic strategy had emerged to specifically target ETS-expressing tumours. Nevertheless, there is evidence that pharmacological inhibition of poly(ADP-ribose) polymerase-1 (PARP-1), a key DNA repair enzyme, specifically sensitises ETS-expressing cancer cells to DNA damage and limits tumour progression by leading some of the cancer cells to death. These effects result from a strong interplay between ETS transcription factors and the PARP-1 enzyme. This review summarises the existing knowledge of this molecular interaction and discusses the promising therapeutic applications. | |
dc.format | Electronic | |
dc.format.extent | 13454 - | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | MDPI | |
dc.relation.ispartof | International Journal of Molecular Sciences | |
dc.subject | DNA damage | |
dc.subject | ETS transcription factors | |
dc.subject | PARP-1 | |
dc.subject | cancer therapy | |
dc.subject | pharmacological inhibition | |
dc.subject | Humans | |
dc.subject | Leukemia | |
dc.subject | Poly Adenosine Diphosphate Ribose | |
dc.subject | Poly(ADP-ribose) Polymerase Inhibitors | |
dc.subject | Prostatic Neoplasms | |
dc.subject | Sarcoma, Ewing | |
dc.title | Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2023-08-28 | |
dc.date.updated | 2023-10-03T09:20:38Z | |
rioxxterms.versionofrecord | 10.3390/ijms241713454 | |
rioxxterms.licenseref.startdate | 2023-08-30 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/37686260 | |
pubs.issue | 17 | |
pubs.organisational-group | ICR | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.3390/ijms241713454 | |
pubs.volume | 24 | |
icr.researchteam | Convergence SC Management | |
dc.contributor.icrauthor | Legrand, Arnaud | |
icr.provenance | Deposited by Dr Arnaud Legrand on 2023-10-03. Deposit type is initial. No. of files: 1. Files: Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition A Promising Therapeutic Strategy for ETS-Expressing Tumours.pdf | |